| Literature DB >> 32696663 |
Jean-Pierre Bassand1,2, Patricia N Apenteng3, Dan Atar4,5, A John Camm6, Frank Cools7, Ramon Corbalan8, David A Fitzmaurice3, Keith Aa Fox9, Shinya Goto10, Sylvia Haas11, Werner Hacke12, Carlos Jerjes-Sanchez13, Yukihiro Koretsune14, Jean-Yves Le Heuzey15, Jitendra Ps Sawhney16, Seil Oh17, Janina Stępińska18, Vincent Ten Cate19, Freek Wa Verheugt20, Gloria Kayani2, Karen S Pieper2, Ajay K Kakkar2,21, For The Garfield-Af Investigators.
Abstract
The Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) examined real-world practice in a total of 57,149 (5069 retrospective, 52,080 prospective) patients with newly diagnosed AF at risk of stroke/systemic embolism, enrolled at over 1000 centers in 35 countries. It aimed to capture data on AF burden, patients' clinical profile, patterns of clinical practice and antithrombotic management, focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants, impact on death and bleeding. GARFIELD-AF set new standards for quality of data collection and analysis. A total of 36 peer-reviewed articles were already published and 73 abstracts presented at international congresses, covering treatment strategies, geographical variations in baseline risk and therapies, adverse outcomes and common comorbidities such as heart failure. A risk prediction tool as well as innovative observational studies and artificial intelligence methodologies are currently being developed by GARFIELD-AF researchers. Clinical Trial Registration: NCT01090362 (ClinicalTrials.gov).Entities:
Keywords: GARFIELD-AF; artificial intelligence (AI); atrial fibrillation (AF); nonvitamin K oral anticoagulant (NOAC); observational study
Year: 2020 PMID： 32696663 DOI： 10.2217/fca-2020-0014
Source DB: PubMed Journal: Future Cardiol ISSN： 1479-6678